| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 277, Issue 4, 2517-2524, January 25, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, May 21, 2001, and in revised form, November 7, 2001
The CBP and p300 co-activators play a key role in
many aspects of gene regulation being recruited to the DNA via
transcription factors that are targets for specific signaling pathways.
It has previously been demonstrated that in neuronal cells the ability of CBP and p300 to activate transcription can be directly stimulated by
nerve growth factor or calcium-activated signaling pathways. Here we demonstrate that, in cardiac cells, the activity of CBP and
p300 is stimulated by phenylephrine (PE) treatment and that they are
required for the activation of atrial naturetic factor (ANF) gene
expression by PE. Activation of CBP/p300 by PE involves the p42/p44
MAPK pathway and targets primarily the N terminus of p300 and the C
terminus of CBP, which are not homologous to one another. To our
knowledge, this is the first report of a specific stimulus modulating
the activity of CBP and p300 in cardiac cells and it suggests that
these factors play an important role in the hypertrophic effect of
PE.
The CBP1 co-activator protein was originally
identified as a factor that interacts with the
CREB transcription factor only following
phosphorylation of CREB on serine 133 (for review see Ref. 1). Thus,
following exposure to cAMP, the CREB factor, which is already bound to
the cAMP-response element (CRE) in its target genes, is phosphorylated
on serine 133 and can then recruit the CBP co-activator, resulting in
cAMP-dependent activation of gene expression (1, 2).
Although originally identified in the cAMP pathway, it is now clear
that CBP and the closely related p300 protein play a key role as
co-activators for a wide variety of transcription factors involved in
various different pathways, including the steroid/thyroid hormone
receptors, AP1, STAT factors, and muscle-specific transcription factors
such as MyoD and MEF2 (for review see Ref. 3).
As expected from this critical role in a variety of aspects of
transcription factor regulation, loss of CBP is incompatible with
survival of the organism. Indeed, even the loss of a single CBP gene (with a functional copy remaining) results in
humans in the severe developmental disorder Rubinstein-Taybi syndrome (4). Interestingly, this disorder as well as its characteristic facial
abnormalities and mental retardation can also result in cardiac
disorders suggesting a role for CBP in the heart (5, 6). In the case of
the closely related p300 protein, such a role has been directly
confirmed by the finding that knockout mouse embryos lacking both
copies of the p300 show abnormal heart development with
reduced trabeculation of the ventricular chambers and weaker/less
extensive heart contractions, which appear to be responsible for the
death of the knockout embryos in utero (7).
Interestingly, the p300 knockout mouse embryos also show
reduced expression of cardiac muscle structural proteins such as myosin
heavy chain and These effects of CBP and p300 on cardiac-specific gene expression are
likely to be mediated via their ability to specifically interact with
transcription factors involved in the regulation of gene expression in
cardiac cells such as the MEF2 transcription factor, which is known to
interact with p300/CBP and to play a key role in regulating
cardiac-specific gene expression (10, 11). Similarly, CBP and p300 can
also interact with transcription factors that have been shown to be
involved in the hypertrophic response of the heart. Thus
CBP/p300-interacting proteins include factors such as AP-1 and STAT-3,
which are involved in the hypertrophic response to factors such as
angiotensin II (12, 13) and cardiotrophin-1 (14, 15).
Hypertrophy is a response to overload in the heart, which initially
results in an adaptive increase in muscle mass, based on the increased
size of cardiac myocytes in the heart but ultimately is deleterious and
results in heart failure (for review see Ref. 16). Evidently, an
understanding of the processes involved in regulating cardiac gene
expression during hypertrophy would be of considerable importance both
in itself and in the development of novel therapies. In view of the
interaction of CBP with transcription factors known to be involved in
hypertrophy, we have studied the effect of hypertrophic agents on CBP
and p300.
Materials--
Urocortin (UCN), Phenylephrine (PE), and
Bt2cAMP were from Sigma Chemical Co. Cardiotrophin-1 (CT-1)
was a kind gift from Dr. D. Pennica (Genentech). The adrenergic
antagonists prazosin and propranolol were also obtained from
Sigma. The specific MAPK inhibitor PD98059 (PD) was from New England
BioLabs. The specific p38 MAPK inhibitor SB203580 (SB) was from
Calbiochem. PKC inhibitor H-7 dihydrochloride was from Tocris and the
PKA inhibitor H-89 dihydrochloride from Calbiochem. Cell culture media
and fetal calf serum were from Invitrogen.
DNA Constructs--
The following Gal4-CBP chimera constructs
have been described previously: Rc/RSV pGal-CBP-(227-460),
pGal-CBP-(721-1679), pGal-CBP-(1678-2441), pGal-(1678-1843),
pGal-CBP-(1844-1956), pGal-CBP-(1961-2039), pGal-CBP-(2060-2179),
pGal-CBP-(2173-2288), pGal-CBP-(2288-2441), and
pGal-CBP-(full-length) (17). The pGal-p300 chimeras Gal4-p300-(1-743),
Gal4-p300-(242-1737), Gal4-p300-(964-1922), Gal4-p300-(1514-1922),
Gal4-p300-(1737-2414), Gal4-p300-(1945-2414) and Gal4-p300
full-length have also been described previously (18). The reporter
plasmid 5xGal4-E1B TATA-luciferase was a kind gift of Dr. R. A. Maurer (19). The expression constructs for constitutively active MEK-1
(SS/DD), wild type p42 MAPK (P42WT), and the dominant negative p42 MAPK
mutant (P42Y185F) were obtained from Dr. J. Pouyssegur (20). The
CREBDIEDML mutant and SS-CRE construct were a kind gift of
Dr. R. H. Goodman (21).
The ANF-luciferase reporter construct ( Cardiac Cell Culture--
Ventricular myocytes were isolated
from the hearts of neonatal rats (Sprague-Dawley) less than 2 days old
and were cultured as described previously (23). Cardiac myocyte cell
suspension was transferred to 24-well (1-cm diameter) gelatin-coated
plates at a density of 106 cells/well in Dulbecco's
modified Eagle's medium supplemented with 15% fetal calf serum. After
24 h the cardiac cultures could be seen to beat in synchrony.
Transfection and Assay of Luciferase Activity--
Transient
transfections of rat neonatal cardiac myocytes were performed using the
calcium phosphate procedure as described by Gorman (24). The amounts of
expression vector used are indicated in the figure legends. For each
transfection, cells were incubated for 20 h in media containing
15% fetal calf serum. Cells were then treated with UCN, PE, CT-1, and
cAMP for 26 h in media supplemented with 1% fetal calf serum. In
some experiments, cells were pretreated with different protein kinase
inhibitors for 10 min before addition of PE. Cells were then harvested
and assayed for luciferase activities according to the manufacturer's
directions (Promega). Results were normalized to protein content as
determined by Bradford protein assay (25).
Western Blotting--
Protein extracts were run on a 10%
acrylamide gel, transferred to Hybond C membrane (Amersham
Biosciences, Inc.), probed with relevant antibody and enhanced
chemiluminescence (Amersham Biosciences, Inc.) was used to visualize
labeled bands by exposure to photographic film. Monoclonal antibodies
against phosphorylated or total p42/p44 were obtained from Santa Cruz Biotechnologies.
Statistics--
Values are given as percent activity relative to
the luciferase in unstimulated cells (set at 100%). Values are
expressed as mean ± S.E. of n experiments. Statistical
analysis was performed by the two-tailed Student's t test
for unpaired data, with p values <0.05 considered
statistically significant.
To analyze the effect of hypertrophic agents on the CBP
transcriptional co-activator, we made use of constructs in which the DNA sequences encoding CBP have been fused to sequences encoding the
DNA binding domain of the yeast Gal 4 transcription factor (17).
Co-transfection of these constructs with a reporter construct containing Gal 4 DNA binding sites upstream of a heterologous promoter
allows DNA binding mediated via the Gal 4 portion of the molecule and
transcriptional activation via the CBP molecule. Hence the effect of
any stimulus on the ability of CBP to activate transcription can be
assessed without any complications arising from it being recruited to
the DNA via interaction with a DNA-bound transcription factor that may
itself be modulated by the stimulus. We have previously used this
system to determine that nerve growth factor stimulates the
transcriptional activating ability of CBP and that this effect is
dependent upon the p42/p44 MAPK pathway (26).
The Gal4/CBP constructs were therefore transfected into neonatal
cardiac cells together with the reporter luciferase construct, and the
cells were either left untreated or exposed to the hypertrophic agents
PE, UCN, or CT-1. In these experiments, a significant enhancement of
promoter activity was observed in the cells transfected with constructs
containing full-length CBP when the activity in untreated cells was
compared with that observed in PE-treated cells (Fig. 1). In contrast, a much smaller
up-regulation was observed with UCN and virtually no enhancement was
observed with CT-1 or cAMP. PE produced no enhanced activity when a
construct containing the isolated DNA binding domain of Gal 4 alone was
transfected, indicating that these effects are mediated via the CBP or
p300 portion of the construct (data not shown). A similar up-regulation
of activity with PE to that seen with full-length CBP was observed with
a Gal 4 construct containing the C-terminal activation domain of CBP (amino acids 1678-2441). In contrast, no enhancement with PE was
observed when a construct containing the N-terminal activation domain
of CBP (amino acids 1-460) was used, indicating that this effect was
specific to the C-terminal activation domain (Fig. 1). The construct
containing the C-terminal activation domain was, therefore, used in our
subsequent mechanistic experiments.
These experiments demonstrate therefore that the hypertrophic agent PE
is able to enhance the transcriptional stimulating ability of CBP in
cardiac cells acting via the C terminus of CBP. In view of this and the
much weaker or no effect noted with UCN or CT-1, we decided to analyze
the effect of PE. Initially to confirm that this effect was mediated
via PE-mediated activation of
The Transcriptional Co-activators CBP and p300 Are Activated via
Phenylephrine through the p42/p44 MAPK Cascade*
§,,,
, and**
Institute of Child Health, University
College London, 30 Guilford St., London WC1N 1EH, United Kingdom, the
¶ Jefferson Cancer Institute, Thomas Jefferson University,
Philadelphia, Pennsylvania 19107, and the Department of
Pharmacology and Physiological Sciences, St. Louis University School of
Medicine, St. Louis, Missouri 63104
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-actinin (8). This parallels previous findings that
the expression of these genes could be inhibited in cultured cardiac
cells by overexpression of the adenovirus E1A protein, which binds p300
and CBP and removes them from cellular transcription factors, thereby
inhibiting the activity of these factors (8, 9). This potential key
role for CBP and p300 in regulating cardiac cell-specific gene
expression is supported by recent data that demonstrate that
doxorubicin appears to promote transcriptional repression in cardiac
cells by specifically mediating the degradation of p300 (10).
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
3003 to +62) of the ANF rat
gene was a kind gift of Dr. K. Knowlton (22). The CBP antisense vector
was constructed by cloning CBP full-length (1-7326) into the
BamHI site of Bluescript SK (Stratagene) in the reversed orientation and subsequently excising the insert with NotI
and SalI and inserting it into a pBI-G expression vector
(CLONTECH). The plasmid containing a dominant
negative mutant of p300 (lacking the C/HI domain, amino acids 348-412)
under the control of the CMV promoter was obtained from Upstate Biotechnology.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (43K):
[in a new window]
Fig. 1.
Effect of different extracellular stimuli on
the transcriptional activity of CBP in cardiac myocytes.
Luciferase assay results of co-transfecting rat neonatal cardiac
myocytes with 2.5 µg of the Gal4-E1B TATA-luciferase with 2.5 µg of
the CBP N-terminal (amino acids 1-460) or C-terminal (amino acids
1678-2441)/Gal4 constructs in the presence or absence of UCN
(10 
7 M), PE (50 µM), CT-1 (1 ng
ml1), and cAMP (1 mM). Values are expressed
relative to the level of luciferase in control, untreated transfected
rat neonatal cardiac myocytes (set at 100%) and are the means of three
independent transfection experiments whose standard error is indicated
by the bars. *, p < 0.05 versus
control.
-adrenergic receptors, we used the
-adrenergic antagonist prazosin and, for comparison, the
-adrenergic antagonist propranolol (27). In these experiments (Fig.
2), prazosin blocked the effect of PE on
CBP-mediated transcriptional activation, whereas propranolol had no
effect, confirming that PE was acting via -adrenergic receptor
stimulation.
View larger version (19K):
[in a new window]
Fig. 2.
Effect of - and
-adrenergic antagonists on the ability of PE to
activate CBP in cardiac myocytes. Luciferase assay results of
co-transfecting neonatal cardiac myocytes with 2.5 µg of the Gal4-E1B
TATA-luciferase and 2.5 µg of the CBP C-terminal (1678-2441)/Gal4
construct in the presence or absence of PE (50 µM), the
-adrenergic antagonist prazosin (5 µM), or the
-adrenergic agonist, propanolol (20 µM). Values are
expressed relative to the level of luciferase in control, untreated
transfected rat neonatal cardiac myocytes (set at 100%) and are the
means of three independent transfection experiments whose standard
error is indicated by the bars. *, p < 0.05 versus control; +, p < 0.05 versus PE alone.
To investigate the mechanisms mediating the effect of PE, the
experiments were repeated in the presence or absence of the inhibitors
PD, which specifically inhibits the activity of the p42/p44 MAPK
pathway, and SB, which inhibits the activity of the p38 MAPK pathway.
In these experiments (Fig. 3) the
up-regulation of CBP activity by PE was unaffected by addition of SB,
indicating that it does not involve the p38 MAPK pathway. In contrast,
addition of PD resulted in a significant fall in the basal activity
produced by the CBP and p300 constructs in the absence of PE and
prevented any stimulatory effect of PE on this transcriptional
activity. This suggests therefore that in cardiac cells the ability of
PE to stimulate the transcriptional activity of CBP involves the p42/p44 MAPK pathway.
|
As expected, Western blotting with an antibody specific for active
phosphorylated p42/p44 MAPK showed a clear activation of both p42 and
p44 by PE. Moreover, this effect was not observed when PE and PD were
added together (Fig. 4).
|
It has previously been shown that activation of p42/p44 MAPK in cardiac myocytes requires activation of protein kinase C but not protein kinase A (27). To test this in our system, we examined the effect of the PKC inhibitor H-7 or the PKA inhibitor H-89 on the ability of PE to activate CBP. As indicated in Fig. 3B, H-7 was indeed able to block activation by PE whereas H-89 had no effect, confirming the role of PKC.
To confirm our experiments with the chemical inhibitor PD, we used a
dominant negative mutant of the p42 MAPK enzyme that contains a single
amino acid substitution replacing tyrosine with phenylalanine and acts
as a dominant negative mutant. In these experiments (Fig.
5A) transfection of an
expression vector encoding this mutant was able to block the ability of
PE to enhance CBP transcriptional activity, whereas transfection of a
control expression vector lacking any insert failed to produce this
effect. This therefore confirms our conclusion that CBP is activated by
PE via the p42/p44 MAPK pathway.
|
Interestingly, transfection of a plasmid encoding wild type p42 resulted in enhanced transcription activating ability of CBP, which was of similar extent to that produced by PE and which was not further enhanced by the addition of PE. This provides further evidence that PE acts via this pathway and hence does not further stimulate transcription in the presence of active p42 MAPK. In agreement with this, a plasmid (SS/DD) encoding a constitutively active form of MEK-1, the upstream activator of p42/p44 MAPK, was also able to stimulate the activity of the CBP construct in the absence of PE (Fig. 5B). Interestingly, this stimulation was blocked by the PKC inhibitor H-7, suggesting that PKC may be downstream of MEK-1 in the pathway by which PE stimulates CBP.
In our previous experiments (26) we demonstrated that the ability of
NGF to stimulate the transcription activating ability of CBP was also
dependent on the p42/p44 MAPK pathway and was observed with constructs
containing two small independent regions at the C terminus of CBP. To
determine whether a similar effect could be observed in the case of PE,
we transfected a wide variety of constructs containing different
N-terminal and C-terminal regions of CBP linked to the Gal 4 DNA
binding domain and analyzed their response to PE. In these experiments
(Fig. 6) a strong response to PE of over
5-fold was observed with the construct containing the region of CBP
from amino acids 1961 through 2039, and smaller responses of
approximately 2-fold were observed with other C-terminal regions. This
suggests that multiple regions at the C terminus of CBP can mediate the
response to PE, but that a single short region produces the strongest
effect.
|
To determine whether this short region showed a similar dependence on
the p42/p44 MAPK pathway for its transcriptional activation by PE, we
carried out experiments in which the effect of PE on this region was
assayed in the presence or absence of PD or of the dominant negative
p42 MAPK pathway. In these experiments (Fig. 7) the strong up-regulation of
transcription activity by PE was prevented by the addition either of PD
or of the dominant negative p42 MAPK construct, and the activity of
this region was enhanced by the construct encoding wild type p42.
Hence, as with the entire C terminus the effect of PE on this small
region of the CBP factor requires the activity of the p42/p44 MAPK
pathway.
|
Evidently, all our experiments investigating the effect of PE on CBP
use Gal4/CBP fusion proteins, and this approach has been criticized,
because of the artificial nature of the constructs used (21). To
confirm our results, we therefore used a mutant form of the CREB
transcription factor, which has been altered so that it constitutively
binds CBP without the need for phosphorylation of serine 133 of CREB
(21). Hence, any effect of a specific agent when this mutant is used
cannot reflect enhanced recruitment of CBP via phosphorylation of CREB.
When a target promoter containing a CREB-binding cAMP-response element
(CRE) was co-transfected into cardiac myocytes with this mutant form of
CREB, transcription was stimulated by PE (Fig.
8) consistent with PE targeting the transcriptional activity of CBP under conditions where any effect on
its recruitment is eliminated.
|
To further extend these studies, we wished to test the role of CBP in
the activation of a natural promoter by PE. To do this we used the
promoter of the atrial naturetic factor (ANF) gene, which is
known to be activated during cardiac hypertrophy and to be stimulated
by PE (22, 28). The activation of this promoter by PE was abolished by
co-transfection of a construct expressing full-length CBP in an
antisense orientation (Fig.
9A). As expected, the
antisense CBP construct also inhibited the response of the SS-CRE
promoter to cAMP, indicating that it was able to prevent a well
characterized effect of CBP (Fig. 9B). Hence, the role of
CBP in the PE response can be demonstrated on a natural promoter by
inhibiting endogenous CBP providing further evidence that it is not
dependent on the use of Gal4-CBP constructs.
|
In view of the close relationship of CBP and p300, we
wished to determine whether PE could also affect the ability of p300 to
stimulate transcription. To do this we used constructs in which different regions of p300 had been linked to the DNA binding domain of
Gal4 (18). In these experiments (Fig.
10) a small non-statistically significant effect of PE was observed with constructs containing the
C-terminal activation domain of p300 (amino acids 1737-2414 or
1945-2414), which is homologous to that found at the same position in
CBP (for review see Refs. 3, 29).
|
Interestingly, however, the strongest stimulation by PE, which was
comparable to that observed with full-length p300, was observed with
the N-terminal activation domain of p300 (amino acids 1-743) even
though no effect of PE was observed with the homologous region of CBP
(compare Figs. 1 and 10). Despite this distinction, activation of the
N-terminal domain of p300 by PE was mediated via p42/p44 MAPK
activation, because it was blocked by PD (Fig.
11A) and by the dominant
negative mutant of p42 MAPK as well as being activated by
overexpression of wild type p42 (Fig. 11B).
|
As in the case of CBP, the role of p300 in the response to PE could be
demonstrated with a natural promoter. Thus, a dominant negative mutant
of p300 (lacking amino acids 348-412) was able to block the activation
of the ANF promoter by PE (Fig. 12) in a similar manner to that observed with the antisense CBP construct.
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
|
|---|
Considerable evidence suggests that activation of the p42/p44 MAPK pathway is critical for the hypertrophic response of cardiac cells. Thus, for example, stimuli that induce hypertrophy such as mechanical load and angiotensin II have been shown to induce activation of this pathway (30, 31). Moreover, a recent study has demonstrated that overexpression of a constitutively active form of MEK1 (which is an upstream activator of the p42/p44 MAPK enzymes) in transgenic mice results in compensated cardiac hypertrophy providing direct evidence that activation of this pathway can induce a hypertrophic response (32).
In the case of PE, initial studies demonstrated that treatment of cardiac cells with this factor was associated with activation of the p42/p44 MAPK pathway (27, 33). Moreover, such activation appears to be necessary for the hypertrophic response induced by PE. Thus, it has been shown that down-regulation of the p42/p44 MAPK enzymes using an antisense approach inhibits the PE-induced hypertrophic response in cardiac myocytes (34), and similar results were subsequently obtained using chemical inhibitors to block activation of the p42/p44 MAPK pathway in response to PE (35, 36).
These data indicate therefore that PE can activate the p42/p44 MAPK pathway and that activation of this pathway plays a key role in its ability to induce the hypertrophic response. The data presented here add a new aspect to this by indicating that PE can stimulate the transcriptional activation ability of CBP and p300 and that this effect is dependent upon its ability to activate the p42/p44 MAPK pathway. To examine such effects on CBP or p300 in the absence of any effect on their recruitment to the DNA, we used constructs in which different regions of CBP or p300 have been linked to the DNA binding domain of Gal4. Although this approach has been extensively used by ourselves and others (17, 18, 26, 37, 38), it has been criticized (21). Here, we have independently confirmed our results using a mutant form of CREB, which constitutively recruits CBP (21). This again allows effects on CBP to be studied in the absence of recruitment effects and has been used to show that some effects observed on Gal4/CBP chimeras cannot be reproduced with this system (21). Moreover, we have used an antisense CBP construct to block the effect of PE on a natural target promoter, that of the ANF gene. Hence, in our case, the effect of PE has been demonstrated using three distinct systems, two of which rely on endogenous CBP rather than Gal4/CBP constructs.
Interestingly, a dominant negative mutant of p300 was also able to block activation of the ANF promoter by PE indicating that the role of p300 in the PE response could also be demonstrated by inhibiting endogenous p300. It is possible that the ability to block the PE response of the ANF promoter by blocking either CBP or p300 reflects distinct functions for these two factors in the stimulation of the promoter, with inhibition of either factor therefore blocking the response. It is more likely, however, that this effect reflects a dependence of the response on the maintenance of the normal total level of functional CBP and p300. Hence, inhibition of either factor reduces the total level of these two closely related factors and therefore inhibits the response. This effect has been observed, for example, in knockout mice where CBP/p300 double-heterozygote animals show a similar lethal phenotype to that observed with the homozygous knockout of either factor alone (for review see Ref. 39).
In our studies, other hypertrophic agents such as UCN and CT-1 did not induce significantly increased activity of CBP. Both these agents have been shown to activate the p42/p44 MAPK pathway (40-42). However, unlike the case of PE, inhibition of p42/p44 MAPK activation does not affect the ability of UCN or CT-1 to induce hypertrophy (14, 42).2 Hence the ability of PE to induce strong enhancement of the transcriptional activation ability of CBP and p300 via the p42/p44 MAPK pathway correlates with the essential role of this pathway in its ability to induce hypertrophy.
These findings suggest therefore the possibility that enhanced transcriptional activity of CBP and p300 may be involved in the induction of hypertrophy by PE. Interestingly, a number of factors involved in the hypertrophic response such as AP-1 and the STAT factors have been shown to associate with CBP and p300 (12, 13). Recent studies of the activation of endothelin-1 (ET-1) gene expression by PE have shown that the transcription factor GATA-4 is phosphorylated by the p42/p44 MAPK pathway following PE treatment and plays a critical role in the activation of ET-1 gene expression, which is required for hypertrophy (43). Moreover, it has been demonstrated that CBP enhances the activation of BNP by GATA-4 and YYI (44) whereas p300 associates with GATA-4 and inhibition of p300 activity by overexpression of E1A prevents GATA-4 stimulation of ET-1 activity (45).
It is likely therefore that CBP and p300 play a critical role in the process of cardiac hypertrophy and, in particular, in its induction by PE. Initial studies of the CBP/CREB system showed that signaling pathways produced phosphorylation of the CREB factor leading to the recruitment of CBP to the DNA and transcriptional activation (1, 2). Studies of this type led to the idea that DNA-bound transcription factors such as CREB represented the primary targets for signaling pathways that induce transcriptional activation with co-activators such as CBP and p300, which in turn recognize the consequences of these signaling pathways acting on the DNA-bound transcription factors rather than being targets themselves for such signaling pathways.
A variety of recent data, however, suggests that CBP and p300 themselves are targets for specific signaling pathways. Thus, for example, in our previous work (26) we demonstrated that NGF was able to enhance the ability of CBP-Gal 4 fusion proteins to activate transcription and that this effect was dependent upon the ability of NGF to activate the p42/p44 MAPK pathway. Similar activation of CBP by calcium-stimulated signaling pathways has been observed in neuronal cells (37, 38, 46). The work presented here extends these studies to show that activation, of p42/p44 MAPK in cardiac cells by PE, similarly results in an enhancement of the transcriptional activation ability of CBP and p300. This indicates that the activity of CBP can be directly targeted by specific signaling pathways in cardiac as well as neuronal cells and identifies PE as an agent able to produce this effect. Moreover, it suggests that, during the hypertrophic response, CBP and p300 are not simply passive partners being recruited to the DNA via phosphorylation of DNA-bound factors such as GATA4. Rather they represent targets for these signaling pathways and will induce enhanced transcriptional activation following PE treatment.
Interestingly, the predominant effect of PE involves the C-terminal domain of CBP and the N-terminal domain of p300 even though these regions are non-homologous to one another (for review see Refs. 3, 29). In contrast, the C-terminal region of p300 was only weakly activated by PE whereas PE had no effect at all on the activity of the N-terminal region of CBP. Hence, the same signaling pathway can target two different regions of these closely related molecules to enhance their transcriptional activating ability.
It is likely that the enhanced transcriptional activating ability of p300 and CBP is mediated via phosphorylation induced by the p42/p44 MAPK pathway. Evidently, the putative phosphorylation sites targeted by the p42/p44 MAPK pathway are likely to be located at the N terminus of p300 whose activity is enhanced by PE (this report) and at the C terminus of CBP whose activity is enhanced by NGF (26) and by PE (this report).
Interestingly, the region of CBP from 1961 to 2039, which mediates the strongest response to PE was also identified as one of two regions at the C terminus of CBP involved in its response to NGF (26) whereas amino acids 2009 to 2117 were found to be able to mediate activation by calcium in neuronal cells (38). Because the PE and NGF effects involve p42/p44 MAPK (26 and this report), whereas the calcium effect requires other kinases such as CaM kinase II and CaM kinase IV (38), this indicates that a small C-terminal region of CBP acts as a target for different kinase-activated signaling pathways. Although the exact sites for phosphorylation by these pathways remain to be identified, it has been demonstrated that p42/p44 MAPK can phosphorylate CBP in vitro on at least two sites within the region 1891-2441 (47). Moreover, we have demonstrated that CBP and p42/p44 MAPK enzymes directly associated with one another and that CBP becomes phosphorylated following NGF treatment (48).
In the case of p300, serine 89 within the N-terminal region targeted by PE has been shown to be phosphorylated by PKC (49). In view of the potential involvement of PKC in the effects we observe, it will be of interest to determine whether this residue is targeted by PE and is responsible for its stimulatory effect.
Although the precise sites that are phosphorylated on CBP and p300
following PE treatment remain to be identified, it is already clear
that the transcriptional activating ability of these critical co-activators is stimulated by the hypertrophic agent PE in a p42/p44
MAPK-dependent manner in cardiac cells and that this is effect is likely to play an important role in the ability of PE to
induce specific gene expression during the hypertrophic response.
| |
FOOTNOTES |
|---|
* This work was supported in part by the British Heart Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Supported by a Ph.D. Studentship from the British Heart Foundation.
** To whom correspondence should be addressed: Institute of Child Health, 30 Guilford St., London WC1N 1EH, United Kingdom. Tel.: 44-20-7905-2189; Fax: 44-20-7242-8437; E-mail: d.latchman@ich.ucl.ac.uk.
Published, JBC Papers in Press, November 8, 2001, DOI 10.1074/jbc.M104626200
2 J. E. Railson, Z. Liao, K. B. Brar, J. C. Buddle, D. Pennica, A. Srephanou, and D. S. Latchman, submitted for publication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: CBP, CREB-binding protein; CREB, cAMP-response element-binding protein; CRE, cAMP-response element; STAT, signal transducers and activators of transcription; UCN, urocortin; CT-1, cardiotrophin-1; MAPK, mitogen-activated protein kinase; MEK1, MAPK/extracellular signal-regulated kinase kinase; PD, PD98059; SB, SB203580; PKA, protein kinase A; PKC, protein kinase C; NF, atrial naturetic factor; CMV, cytomegalovirus; PE, phenylephrine; ET-1, endothelin-1; NGF, nerve growth factor; CaM, calmodulin; Bt2cAMP, dibutyryl cAMP; H-7, dihydrochloride; H-89, dihydrochloride.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
|
|---|
| 1. | Lalli, E., and Sassone-Corsi, P. (1994) J. Biol. Chem. 269, 17359-17362 |
| 2. | Chrivia, J. C., Kwok, R. P. S., Lamb, N., Hagiwara, M., Montminy, M. R., and Goodman, R. H. (1993) Nature 365, 855-859 |
| 3. | Shikama, N., Lyon, J., and La Thangue, N. B. (1997) Trends Cell Biol. 7, 230-236 |
| 4. | Petrij, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C. M., Masuno, M., Tommerup, N., van Ommen, G. J. B., Goodman, R. H., Peters, D. J. M., and Breunig, M. H. (1995) Nature 376, 348-351 |
| 5. | Rubinstein, J. H., and Taybi, H. (1963) Am. J. Dis. Child. 105, 588-608 |
| 6. | Henneken, R. C. M., Van Den Boogaard, M. J., Sibbles, B. J., and Van Spijker, H. G. (1990) Am. J. Med. Genet. Suppl. 6, 17-29 |
| 7. | Yao, T.-P, Oh, S. P., Fuchs, M., Zhou, N.-D., Ch'ng, L.-E., Livingston, D. M., and Eckner, R. (1998) Cell 93, 361-372 |
| 8. | Hasegawa, K., Meyers, M. B., and Kitsis, R. N. (1997) J. Biol. Chem. 272, 20049-20054 |
| 9. | Bishopric, N. H, Zeng, G-Q, Sato, B., and Webster, K. A. (1997) J. Biol. Chem. 272, 20584-20594 |
| 10. | Poizat, C., Sartobelli, V., Chung, G., Kloner, R. A., and Kedes, L. (2000) Mol. Cell. Biol. 20, 8643-8654 |
| 11. | Eckner, R., Yao, Y.-P., Oldread, E., and Livingston, D. M. (1996) Genes Dev. 10, 2478-2490 |
| 12. | Herzig, T. C., Jobe, S. M., Aoki, H., Molkentin, J. D., Cowley, A. W., Jr., Izumo, S., and Markham, B. E. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7543-7548 |
| 13. | Mascareno, E., Dhar, M., and Siddiqui, M. A. Q. (1998) Cell Biol. 95, 5590-5594 |
| 14. | Kunisada, K., Tone, E., Fujio, Y., Matsui, H., Yamauchi-Takihara, K., and Kishimoto, T. (1997) Circulation 98, 346-352 |
| 15. | Fukuzawa, J., Booz, G. W., Hunt, R. A., Shimizu, N., Karoor, V., Baker, K. M., and Dostal, D. E. (2000) Hypertension 35, 1191-1196 |
| 16. | Van Bilsen, M., and Chien, K. R. (1993) Cardiovasc. Res. 27, 1140-1149 |
| 17. | Swope, D. L., Mueller, C. L., and Chrivia, J. C. (1996) J. Biol. Chem. 271, 28138-28145 |
| 18. | Yuan, W., Condorelli, G., Caruso, M., Felsani, A., and Giordano, A. (1996) J. Biol. Chem. 271, 9009-9013 |
| 19. | Sun, P., Enslen, H., Myung, P. S., and Maurer, R. A. (1994) Genes Dev. 8, 2527-2539 |
| 20. | Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., and Pouysségur, J. (1996) J. Biol. Chem. 271, 20608-20616 |
| 21. | Cardinaux, J.-R., Notis, J. C., Zhang, Q., Vo, N., Craig, J. C., Fass, D. M., Brennan, R. G., and Goodman, R. H. (2000) Mol. Cell. Biol. 20, 1546-1552 |
| 22. | Knowlton, K. U., Baracchini, E., Ross, R. S., Harris, A. N., Henderson, S. A., Evans, S. M., Glembotski, C. C., and Chien, K. R. (1991) J. Biol. Chem. 266, 7759-7768 |
| 23. | Simpson, P. S., and Savion, S. (1982) Circ. Res. 50, 101-116 |
| 24. | Gorman, C. M. (1985) in DNA Cloning, A Practical Approach, vol. 2 (Glover, D. M., ed) , pp. 143-190, IRL Press, Oxford, UK |
| 25. | Bradford, M. M. (1976) Analyt. Biochem. 72, 248-254 |
| 26. | Liu, Y. Z., Chrivia, J., and Latchman, D. S. (1998) J. Biol. Chem. 273, 32400-32407 |
| 27. | Bogoyevitch, M. A., Andersson, M. B., Gillespie-Brown, J., Clerk, A., Glennon, P. E., Fuller, S. J., and Sugden, P. H. (1996) Biochem. J. 314, 115-121 |
| 28. | Lee, R. T., Bloch, K. D., Pfeffer, J. M., Pfeffer, M. A., Neer, E. J., and Seidman, C. E. (1988) J. Clin. Invest. 81, 431-434 |
| 29. | Giordano, A., and Avantaggiati, M. L. (1999) J. Cell. Physiol. 181, 218-230 |
| 30. | Yamazaki, T., Tobe, K., Hoh, E., Maemura, K., Kaida, T., Komuro, I., Tamemoto, H., Kadowaki, T., Nagai, R., and Yazaki, Y. (1993) J. Biol. Chem. 268, 12069-12076 |
| 31. | Zou, Y., Komuro, I., Yamazaki, T., Aikawa, R., Kudoh, S., Shiojima, I., Hiroi, Y., Mizuno, T., and Yazaki, Y. (1996) J. Biol. Chem. 271, 33592-33597 |
| 32. | Bueno, O. F., De, Windt, L. J., Tymitz, K. M., Witt, S. A., Kimball, T. R., Klevitsky, R., Hewett, T. E., Jones, S. P., Lefer, D. J., Peng, C.-F., Kitsis, R. N., and Molkentin, J. D. (2000) EMBO J. 19, 6341-6350 |
| 33. | Bogoyevitch, M. A., Glennon, P. E., and Sugden, P. H. (1993) FEBS Lett. 317, 271-275 |
| 34. | Glennon, P. E., Kaddoura, S., Sale, E. M., Sale, G. J., Fuller, S. J., and Sugden, P. H. (1996) Circ. Res. 78, 954-961 |
| 35. | Clerk, A., Michael, A., and Sugden, P. H. (1998) J. Cell Biol. 142, 523-535 |
| 36. | Yue, T.-L., Gu, J.-L., Wang, C., Reith, A. D., Lee, J. C., Mirabile, R. C., Kreutz, R., Wang, Y., Maleeff, B., Parsons, A. A., and Ohlstein, E. H. (2000) J. Biol. Chem. 275, 37895-37901 |
| 37. | Chawla, S., Hardingham, G. E., Quinn, D. R., and Bading, H. (1998) Science 281, 1505-1509 |
| 38. | Hu, S.-C., Chrivia, J., and Ghosh, A. (1999) Neuron 22, 799-808 |
| 39. | Goodman, R. H., and Smolik, S. (2000) Genes Dev. 14, 1553-1577 |
| 40. | Brar, B. K., Jonassen, A. K., Stephanou, A. S., Santilli, G., Railson, J. E., Knight, R. A., Yellon, D. M., and Latchman, D. S. (2000) J. Biol. Chem. 275, 8508-8514 |
| 41. | Sheng, Z., Knowlton, K., Chen, J., Hoshijima, M., Brown, H., and Chien, K. R. (1997) J. Biol. Chem. 272, 5783-5791 |
| 42. | Brar, B. K., Stephanou, A., Liao, Z., O'Leary, R. M., Pennica, D., Yellon, D. M., and Latchman, D. S. (2001) Cardiovasc. Res. 51, 265-274 |
| 43. | Morimoto, T., Hasegawa, K., Kaburagi, S., Kakita, T., Wada, H., Yanazume, T., and Sasayama, S. (2000) J. Biol. Chem. 275, 13721-13726 |
| 44. | Bhalla, S. S., Robitaille, L., and Nemer, M. (2001) J. Biol. Chem. 276, 11439-11445 |
| 45. | Morimoto, T., Kakita, T., Wada, H., and Hasegawa, K. (2000) Abstracts of the American Heart Association Annual Meeting, Abstr. 1060, Lippincott, Williams, and Wilkins, Baltimore, MD |
| 46. | Janknecht, R., and Nordheim, A. (1996) Biochem. Biophys. Res. Commun. 228, 831-837 |
| 47. | Hardingham, G. E., Chawla, S., Cruzalegui, F. H., and Bading, H. (1999) Neuron 22, 789-798 |
| 48. | Liu, Y. Z, Thomas, N. S. B., and Latchman, D. S. (1999) Neuroreport 10, 1239-1243 |
| 49. | Yuan, L. W., and Gambee, J. E. (2000) J. Biol. Chem. 275, 40946-40951 |
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Thangavel and B. H. Shapiro Inherent Sexually Dimorphic Expression of Hepatic CYP2C12 Correlated with Repressed Activation of Growth Hormone-Regulated Signal Transduction in Male Rats Drug Metab. Dispos., September 1, 2008; 36(9): 1884 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. N. Tsai, T. K. S. Ku, N. K. Salib, and D. L. Crowe Extracellular Signals Regulate Rapid Coactivator Recruitment at AP-1 Sites by Altered Phosphorylation of both CREB Binding Protein and c-jun Mol. Cell. Biol., July 1, 2008; 28(13): 4240 - 4250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang and H. J. Forman Acrolein Induces Heme Oxygenase-1 through PKC-{delta} and PI3K in Human Bronchial Epithelial Cells Am. J. Respir. Cell Mol. Biol., April 1, 2008; 38(4): 483 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Chen, Y.-N. Wang, and W.-C. Chang ERK2-mediated C-terminal Serine Phosphorylation of p300 Is Vital to the Regulation of Epidermal Growth Factor-induced Keratin 16 Gene Expression J. Biol. Chem., September 14, 2007; 282(37): 27215 - 27228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Li, H. Yin, Y.-Y. Yao, B. Shen, M. Bader, L. Chao, and J. Chao Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3{beta} activation Cardiovasc Res, January 1, 2007; 73(1): 130 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Frigo, A. Basu, E. N. Nierth-Simpson, C. B. Weldon, C. M. Dugan, S. Elliott, B. M. Collins-Burow, V. A. Salvo, Y. Zhu, L. I. Melnik, et al. p38 Mitogen-Activated Protein Kinase Stimulates Estrogen-Mediated Transcription and Proliferation through the Phosphorylation and Potentiation of the p160 Coactivator Glucocorticoid Receptor-Interacting Protein 1 Mol. Endocrinol., May 1, 2006; 20(5): 971 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Yujnovsky, J. Hirayama, M. Doi, E. Borrelli, and P. Sassone-Corsi Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1 PNAS, April 18, 2006; 103(16): 6386 - 6391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, H. Liu, K. E. Iles, R.-M. Liu, E. M. Postlethwait, Y. Laperche, and H. J. Forman 4-Hydroxynonenal Induces Rat {gamma}-Glutamyl Transpeptidase through Mitogen-Activated Protein Kinase-Mediated Electrophile Response Element/Nuclear Factor Erythroid 2-Related Factor 2 Signaling Am. J. Respir. Cell Mol. Biol., February 1, 2006; 34(2): 174 - 181. [Abstract] [Full Text] |
